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Background: The rate of target lesion revascularization (TLR) against heavily
calcified coronary lesions is still high and remaining unresolved problem even in drug-
eluting stent (DES) era.The aim of this study was to evaluate the outcome of patients
with these lesions undergoing rotational atherectomy (RA) followed by implantation
of second-generation DES.
Methods: We performed coronary intervention using Zotarolimus or Everolimus
eluting stent against consecutive de-novo 893 lesions/590 patients since May 2009 to
October 2010. Angiographical follow-up (mean; 198±88.6 days, range; 164-346 days)
was performed in 718 lesions/451 patients. We divided these lesions into 2 groups.
One is heavily calcified coronary lesions required RA (HCCL), the other is not heavily
calcified lesions without the need of RA (NHCCL). HCCL comprised of 135 lesions,
92 were treated with Zotarolimus-eluting stent (ZES) and 43 were with Everolimus-
eluting stent (EES). NHCCL comprised of 583 lesions, 355 were with ZES and 228
were with EES. We compared clinical safety and efficacy between 2 groups.
Results: The total lesion length was longer in HCCL (21.6±19.0 vs. 17.4±6.3 mm,
p<0.05), although reference diameter was larger in HCCL (3.06±0.46 vs. 2.78±0.48
mm, p<0.05). The maximum burr size of rotablator per lesion was 1.73±0.15 mm. The
ratio of successful stent delivery was 100% in HCCL and 99.8% in NHCCL (p=0.63).
Procedural success rate was equivalent in both groups (90.4% vs. 93.7%, p=0.20) and
there was no in-hospital major advertise cardiac events (MACE) difference (0% vs.
0.4%, p=0.30). At 6 months, the rate of TLR was 3.7% in HCCL vs. 6.3% in NHCCL
(p=0.46), and there were no differences in the ratio of MACE between 2 groups (3.7
% in HCCL vs. 6.7% in NHCCL, p=0.30).
Conclusion: Second-generation DES implantation using RA to facilitate dilatation
against heavily calcified lesions appears to be feasible including high rate of procedural
success rate and low-incidence of TLR as well as the results in non-heavily calcified
lesions.
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Background: The patterns of disease and clinical risk profile of patients being treated
with percutaneous coronary intervention (PCI) is becoming increasingly complex.
There is a strong move towards adopting risk stratification. Several clinical PCI risk
scores exist, but generally include little data on the location, severity or complexity of
lesions. Conversely, the SYNTAX score, designed to characterise the disease pattern
in the SYNTAX study (patients with 3 vessel and left main disease) includes no clinical
data. We aimed to investigate the value of combining SYNTAX with a clinical risk
score to predict 30day and 1 year mortality after PCI
Methods: We reviewed the clinical and angiographic records of all patients who
underwent PCI in 2006 at Sheffield, a regional public cardiothoracic centre (>50%
patients having acute coronary syndromes). In prior work we had already constructed
a clinical PCI risk score appropriate for our institution (Sheffield Risk Score, SRS),
appropriately validated. This, and the SYNTAX score, was calculated for our cohort.
Univariate analyses were carried out for each variable with 30 day and 1 year mortality.
Logistic regression was used to create risk prediction models, which were assessed for
their discrimination and calibration using ROC curves and the Hosmer-Lemeshow test
Results: 1670 PCIs were studied. All relevant clinical variables and the SYNTAX
score were strongly associated with mortality at 30 days and 1 year (p<0.001). ROC
curve analysis showed no improvement in c-statistics [measuring accuracy of
prediction] for the combination of SYNTAX and SRS vs SRS alone for mortality at
30 days (c=0.93 vs 0.91) and 1 year (c=0.83 vs 0.83), despite patients in the highest
SYNTAX tertile (score >15) having, as expected, lower survival at 30d (96 vs 99%)
and 1y (94 vs 98%) than the lower two tertiles combined (p < 0.001).
Conclusion: The combination of SYNTAX score with a clinical PCI risk score does
not result in any significant improvement in the accuracy of predicting survival at 30
days or 1 year in an all-comers population undergoing PCI.
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Background: The increasing use of coronary stenting has improved the outcome of
PCI in several patient cohorts, including female patients. However, more information
about the long term outcomes for women treated in the course of acute coronary
syndrome (ACS) is needed. We investigated the late clinical outcomes in female
patients as compared to males presenting with ACS and treated with a new generation
drug eluting stent coated abluminally with Biolimus A9 and biodegradable polymer.
Methods: Among 3067 consecutive patients treated with Nobori DES and enrolled in
NOBORI2 study, 372 female and 1268 male patients presented in the course of ACS.
Primary endpoint of the study was target lesion failure (TLF), a composite of cardiac
death, target vessel related MI and target lesion revascularization (TLR) at 1 year. Data
are entered in an electronic database; adverse events are adjudicated by an independent
clinical event committee and an independent corelab analyses all angiograms.
Results: Female patients were older, had significantly higher incidence of diabetes
and hypertension and presented with more comorbidities compared to males. However,
they had less previous revascularizations and history of smoking. Lesion complexity
was similar, but more male patients had bifurcation lesions. Number of lesions treated
and stents implanted was lower in female patients. Except higher RVD and diameter
stenosis post-procedure in male vs female, the majority of QCA assessed parameters
were not significantly different. At 2 year follow-up TLF was slightly higher in female
patients (7.3% vs 5.7%; p=NS). In female group 12 patients died of a cardiac cause
(3.2%), 13 (3.5%) had an MI and 17 (4.6%) a TLR. In male group, 25 patients (2.0%)
died, 32 (2.5%) had an MI and 41 (3.2%) a TLR. Stent thrombosis was also slightly
more frequently reported in female patients (1.0% male vs 1.9% female patients;
p=NS).
Conclusion: Despite higher age, more frequent presence of risk factors and co-
morbidities in female patients, clinical outcomes two years after treatment for ACS
were comparably excellent in both genders.
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Background: Previous data from randomized trials and registries demonstrated that
paclitaxel-eluting stent (PES) was as safe and effective in both men and women, except
for a slightly higher revascularization rate in women among the highest risk population.
We performed a sub-analysis of Japan TAXUS Express2 post-marketing survey registry
to assess the influence of gender on clinical outcomes after implantation of PES in
Japanese patients with coronary artery disease.
Methods: We analyzed 2132 PES-treated Japanese patients (women, n=551) from this
real world registry. Study patients were stratified by gender to compare 1 year clinical
outcome.
Results: PES-treated women were older (71.9±8.4 vs. 67.0±9.6, p<0.0001) and more
likely to be insulin treated diabetes and hypertension. By contrast, PES-treated men
were more likely to be smoker, had a previous history of myocardial infarction, and
lower ejection fraction. Angiographically, women had significantly smaller reference
vessel size (2.46±0.53 vs. 2.59±0.60 mm, p<0.0001). At 1 year follow-up, cardiac
death, myocardial infarction and stent thrombosis (ARC definite or probable) were
similar between men and women. Target lesion revascularization rate was significantly
lower in women than in men (4.2 % vs. 6.5 %, p<0.05). Major adverse cardiac event
showed a trend toward lower in women than in men (6.4% vs. 8.8 %, P=0.08).
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Conclusion: Despite higher risk profile, Japanese women treated with PES tended to
have better clinical outcome than PES-treated men at 1 year.
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Background: Bivalirudin is associated with superior safety and economic outcomes
with similar efficacy over heparin plus a glycoprotein IIb/IIIa inhibitor (GPI) in
percutaneous intervention (PCI). While gender and diabetes are significant drivers of
clinical and economic outcomes, it is unclear if bivalirudin maintains its advantages
over heparin plus GPI in an unselected group of these high-risk patients.
Methods: Using the Premier Perspective Database, one of the largest administrative
US databases of hospital clinical and economic outcomes, female patients with diabetes
who had undergone PCI between 2004 and 2010 were identified. Primary endpoints
of in-hospital mortality, clinically apparent bleeding, post-PCI length of stay, and
hospitalization costs were compared between patients treated with bivalirudin versus
heparin plus GPI. Data were unadjusted and propensity score matched.
Results: Data from 61,791 diabetic women was examined in the unadjusted population.
Women over 70 years of age and those pre-treated with clopidogrel were more likely
to receive bivalirudin (61% and 64%, respectively; p<0.03); whereas those with STEMI
or shock were more likely to be treated with heparin plus GPI (81% and 78%
respectively; p<0.01). In-hospital mortality and all bleeding parameters were lower in
the bivalirudin group. In contrast, post-PCI length of stay and total adjusted hospital
costs were significantly greater in the heparin group. When a propensity score matching
method was used to minimize baseline differences between comparison groups, all
clinical and economic outcomes remained significantly lower in the bivalirudin-treated
female diabetics, table 1.
“BIV” = Bivalirudin
“HEP + GPI” = Heparin plus glycoprotein IIb/IIIa inhibitor
“PCI” = percutaneous intervention
“US” = United States
Conclusion: In this large population of high-risk patients, real-world bivalirudin use
in diabetic women undergoing PCI is associated with lower rates of in-hospital
mortality, bleeding, transfusion, post-PCI length of stay, and lower hospitalization costs
compared with the use of heparin plus GPI in unadjusted and propensity score matched
populations.
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Background: The impact of gender on the long-term (greater than 1 year) outcomes
of patients with acute myocardial infarction who have undergone primary PCI is not
well established.
Methods: We examined 3 year outcomes from the large-scale, randomized
HORIZONS-AMI trial according to sex. We used Cox proportional-hazards methods
with stepwise selection using entry and exit criteria of p <0.1 to determine the
independent predictors of MACE, major bleeding and death. Candidate variables tested
were sex; age; diabetes; hypertension; history of smoking; prior MI; prior PCI; prior
CABG; Killip class >1; baseline anemia; creatinine; and symptom onset to balloon
time.
Results: Compared with men, women were significantly older and had higher
prevalence of hypertension and hyperlipidemia (all p<0.05). In contrast, women were
less likely to have a prior history of MI, PCI, CABG and were less likely to be smokers
(all p<0.05). Women were less likely to undergo primary PCI in favor of medical
management (p<0.05). They had longer symptom to balloon time (p=0.007). Female
gender was associated with increased MACE, death and major bleeding at 3 year
follow-up (Table). After multivariable analysis female gender remained an independent
predictor of major bleeding, but not of MACE or death.
Patient Outcomes at 3 years
MACE = Major adverse cardiovascular events, composite of death, reinfarction,
stroke, ischemic TVR; CABG= coronary artery bypass graft; TVR = target vessel
revascularization; ST = stent thrombosis
Conclusion: In the HORIZONS-AMI trial, women had a more unfavorable
cardiovascular risk profile compared with men. Female gender was an independent
predictor of long-term major bleeding (HR[95%CI] = 1.77 [1.38, 2.27], P<0.0001, but
not of death (0.92 [0.68, 1.26], P=0.62) or overall MACE (1.17 [0.98, 1.40], P=0.08).
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Background: Although female patients are at high risk for unfavorable outcomes after
STEMI, the independent predictors of major adverse cardiac events (MACE) at long
term follow up have not been described.
Methods: We examined 3-year outcomes of female patients (n=842) from the large-
scale, prospective, multicenter, HORIZONS-AMI trial where patients were randomized
to receive heparin plus glycoprotein IIb/IIIa inhibitor or bivalirudin, and paclitaxel
eluting stents or bare metal stents in a 2 by 2 factorial design. After the performance
of univariate analysis, we used Cox proportional-hazards methods with stepwise
selection using entry and exit criteria of p<0.1 to determine the independent predictors
of MACE, mortality and reinfarction. Candidate variables tested were age,
hypertension, diabetes, history of smoking, peripheral vascular disease, family history
of premature CAD, prior MI, prior PCI, prior CABG, Killip Class on presentation, and
door to balloon time.
Results: The median age was 66 (95% CI 57.1-75.3), 51% were smokers, 19% had
diabetes, 3.3% had chronic renal insufficiency. The 3- year rates of mortality,
reinfarction and MACE were 8.2%, 7.1% and 24% respectively. The table summarizes
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